Researchers urge policy action as injectable PrEP remains out of reach for many

Researchers urge policy action as injectable PrEP remains out of reach for many

In a new brief report, researchers caution against repeating past mistakes in HIV prevention, as high drug prices and insurance coverage issues have slowed uptake of long-acting, bimonthly injectable pre-exposure prophylaxis (PrEP) in recent years. They warn that these same challenges are poised to undermine the implementation of the newly approved twice-yearly form of injectable PrEP.